<DOC>
	<DOC>NCT02187003</DOC>
	<brief_summary>This is a clinical study evaluating the efficacy and safety of rivipansel (GMI-1070) in treating subjects with sickle cell disease (SCD) who are 6 years of age or older experiencing a pain crisis necessitating hospitalization.</brief_summary>
	<brief_title>Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<criteria>At least 6 years of age. Documented diagnosis of sickle cell disease. Diagnosis of vasoocclusive crisis necessitating admission to the hospital with treatment including IV opioids. Able to receive the first dose of study drug within 24 hours from the administration of IV opioids. Serious systemic infection Acute Chest Syndrome Serious concomitant medical problems (for example, stroke) SCD pain atypical of VOC Severe renal or hepatic impairment Chronic pain rather than a presentation of acute VOC</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Cell Disorders</keyword>
	<keyword>pain crisis</keyword>
	<keyword>vaso-occlusive crisis</keyword>
	<keyword>rivipansel</keyword>
	<keyword>GMI-1070</keyword>
	<keyword>selectin inhibitor</keyword>
	<keyword>SCD</keyword>
	<keyword>VOC</keyword>
</DOC>